Bekinda (ondansetron controlled-release) / RedHill, Hyloris Pharma - LARVOL DELTA

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties (PRNewswire) - "RedHill Biopharma Ltd...announced that it has entered into an exclusive worldwide development and commercialization licensing agreement, excluding North America (the 'Agreement'), with Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) ('Hyloris') for RedHill's RHB-102 (Bekinda)...Under the terms of the Agreement, Hyloris will pay RedHill an upfront payment, in addition to up to $60 million in potential milestone payments, contingent upon achieving specified commercial targets, plus up to mid-20s percent royalties on revenues, subject to certain cost recoupments, with minimum annual payments to RedHill, in return for exclusive rights to RHB-102 across all indications and territories outside the United States, Canada and Mexico."

Commercial • Chemotherapy-Induced Nausea and Vomiting • Gastrointestinal Disorder • Oncology

"Dr. D'Amico shares a moving story about the extraordinary power of ordinary everyday kindness. #ASCO23 Voice. #BeKindAlways" (@Dr_M_Tejani)

RedHill's RHB-102 (BEKINDA) and Opaganib Granted New Patents in Oncology Setting (PRNewswire) - "RedHill Biopharma Ltd...announced the granting of two new EU and U.S. patents for RHB-102 (BEKINDA) and opaganib, respectively, in the oncology setting. The European Patent Office granted RHB-102 (BEKINDA), a 24-hr bimodal release, once-daily oral tablet formulation of ondansetron, a patent covering antiemetic extended-release solid dosage forms for the prevention of nausea and vomiting (CINV/RINV). The patent provides the potential for UK and EU protection of RHB-102 to March 2034....Additionally, the U.S. Patent and Trademark Office (USPTO) has granted a new patent for opaganib in respect to combination compositions for treatment of cancer, extending protection to October 2036."

Patent • Chemotherapy-Induced Nausea and Vomiting • Oncology

"$RDHL RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting https://t.co/5I0MqIgYLc #patent #investing" (@stock_titan)

Oncology

"Brilliant 👏🏻 🔴⚪️⚫️ #GlazersOut #FullSaleOnly #NoToIneos #MUFC_FAMILY #BeKindAlways" (@ForeverM_U_F_C)

"👏👏👏👏 Thank a Resident by taking action to ensure they survive 🧠😵‍💫 during training … & beyond #BeKindAlways #payitforward" (@GDutcherMD)

RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA) for Oncology Support (PRNewswire) - "RedHill Biopharma Ltd...announced that following a positive pre-MAA meeting it plans to submit a Marketing Authorisation Application (MAA) to the UK Medicines & Healthcare products Regulatory Agency (MHRA) seeking approval for RHB-102 (Bekinda) for oncology support (management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, also referred to as CINV and RINV) in adults and children over the age of 12."

European regulatory • Chemotherapy-Induced Nausea and Vomiting • Oncology

"All of “disappointments”along my journey taught me important life lessons #gratitude #educationiskey #friendship #family ❤️🌈😎🦋 #BeKindAlways @nakhtermd @AkhilNarangMD @docbfreed @ALewisMD @WilcoxHeart @NMHheartdoc @RigolinVera" (@PattiVassalloMd)

"#puckdogecoin @dogecoin go to #skisshool #boobs @greengodict @urbandictionary @CambridgeWords @MacDictionary @readingrainbow @betterworldbook #bekindtoeachother #bekindalways #haveasenseofhumour @CandidDotOrg #GenuineQuestion @EricRWeinstein @edgeonline #ALIENWARE #LoveTwitter" (@johnehucker)

"#bekindalways" (@Sandeepan1702)

[VIRTUAL] RedHill Biopharma (BIO 2020) - "RedHill’s key clinical late-stage development programs include: RHB-104, RHB-204, RHB-102 (Bekinda®), ABC294640 (Yeliva®), RHB-106 and RHB-107. More information about the Company is available at www.redhillbio.com."

Oncology

RedHill Biopharma reports third quarter 2018 financial results and business highlights (GlobeNewswire) - "Research and Development Expenses for the third quarter of 2018 were $6.6 million, a decrease of 18% from the third quarter of 2017. The decrease was mainly due to the finalization of the Phase III study with RHB-104 and completion of the clinical studies with BEKINDA® (RHB-102)."

Commercial • Immunology • Inflammation • Inflammatory Bowel Disease

RedHill Biopharma Company Presentation (BIO 2019) - "RedHill has successfully completed four Phase 3 studies (2x Talicia® (RHB-105) for H. pylori infection, RHB-104 for Crohn’s disease & BEKINDA® (RHB-102) for gastroenteritis). RedHill plans to file an NDA for Talicia® for H. pylori infection in H1/2019 (eligible for 6-month priority review) and expects to launch Talicia® in Q4/2019, subject to FDA approval."